Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study

Who can take part

• Patients with:; At least one confirmed diagnosis of AA registered during the baseline period, or; At least one confirmed diagnosis of idiopathic thrombocytopenic purpura (International Classification of Diseases, 10th Revision [ICD10] code: D69.3) registered before the index date and at least one confirmed diagnosis of AA during the follow-up period
• Had at least 6 months of continuous enrolment prior to the index date; Confirmed diagnosis was defined as having ≥1 inpatient or ≥2 outpatient claims with a relevant ICD-10 code and without any doubtful flag; Continuous enrolment (being continuously followed in the database) was defined as having at least one claim every semester
• Had at least one confirmed diagnosis of AA registered before the index date,
• Had at least one procedure for any type of transfusion such as red blood cell transfusion, platelet transfusion, or granulocyte transfusion registered during the baseline period or within 4 weeks after the index date,
• Had at least 6 months of continuous enrolment prior to the index date,
• Had at least a 6-month follow-up period

Who cannot take part

• Not receiving ATG, CSA, ETB or romiplostim (ROM) during the selection period,
• Not receiving ATG, CSA, ETB or ROM during the selection period,
• Had a diagnosis of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelofibrosis, other hematological malignancies, or cataract before the index date; Inclusion and exclusion criteria for the effectiveness population:
• Had a diagnosis of AML, CMML or other hematological malignancies before the index date
• Had at least one prescription of ATG, CSA, ETB or ROM before the index date,

Other criteria

• Inclusion and exclusion criteria for the safety population: